In the field of rare diseases, there is a condition whose diverse and nonspecific symptoms are often misdiagnosed as rheumatoid arthritis, chronic nephritis, or heart failure, among other common illnesses. The average delay from initial symptoms to final diagnosis can be 10–20 years, with some patients experiencing delays exceeding twenty years.
Many people experience burning pain in their limbs, recurrent abdominal pain, or decreased sweating since childhood, yet spend years being referred between neurology, rheumatology, and gastroenterology departments; only when severe organ damage such as kidney failure or myocardial hypertrophy occurs do they gradually approach the true diagnosis.
This disease is Fabry disease—a genetic metabolic disorder first reported in 1898. However, more than a century later, misdiagnosis and delayed diagnosis remain a global challenge.
Through long-term patient interaction, DengYueMed, focusing on the accessibility of drugs for rare diseases, has discovered that what affects prognosis is often not the availability of treatment, but rather the timely identification and early initiation of standardized medication.
This article will systematically outline what Fabry disease is? How to diagnose and treat it? why it is easily overlooked?
I. What is Fabry Disease?
Fabry disease is an X-linked lysosomal storage disorder caused by a deficiency or insufficient activity of α-galactosidase A (α-Gal A), leading to the gradual deposition of globulin-3 ceramide (Gb3) in various tissues, including the vascular endothelium, nerves, kidneys, and heart.
The global prevalence is estimated at approximately 1 in 40,000 to 117,000 male newborns. However, newborn screening studies suggest that the actual detection rate may be higher for late-onset cases, indicating that the disease is still significantly underestimated in the general population.
If not diagnosed and treated promptly, patients often develop serious organ complications in middle age, such as progressive renal failure, myocardial hypertrophy or arrhythmias, and cardiovascular events such as stroke, significantly impacting quality of life and life expectancy.
Genetic Characteristics of Fabry Disease
Fabry disease is an X-linked genetic disorder with significant sex differences:
● Male patients have only one X chromosome. Once they carry the pathogenic mutation, they usually present with typical symptoms. All their daughters inherit the abnormal X chromosome, while their sons are unaffected.
● Female carriers or patients have two X chromosomes. In each pregnancy, they have a 50% chance of passing the abnormal gene to either a son or a daughter. Due to random X chromosome inactivation (Lyonization), the clinical manifestations in women vary greatly, ranging from almost no symptoms to severe involvement of the heart, kidneys, or nervous system.
Currently, over 1000 GLA gene variants have been identified. Different mutation types are closely related to the degree of residual enzyme activity, thus affecting the age of onset, disease severity, and the spectrum of affected organs.
Clinical Manifestations of Fabry Disease
(1) Childhood or Adolescence
● Burning pain in the extremities (abnormal sensation in the extremities)
● Hypophidrosis or anhidrosis
● Whorled corneal opacity
● Gastrointestinal pain and diarrhea
● Angiokeratoma of the skin
These symptoms lack specificity and are the main cause of misdiagnosis.
(2) Adulthood Organ Damage
● Kidneys: Proteinuria, chronic renal failure
● Heart: Left ventricular hypertrophy, arrhythmia
● Central nervous system: Transient ischemic attack or stroke
Multiple international registry studies and regional cohort studies consistently show that there is often a significant delay from the onset of the first symptoms to the final diagnosis of Fabry disease, averaging about 10–20 years, with some patients experiencing close to or exceeding 20 years.
II. How is Fabry Disease Diagnosed?
The diagnosis of Fabry disease usually requires a combination of biochemical and genetic testing, with each playing a different role in patients of different genders.
1. α-Gal A Activity Detection
●Male: Due to having only one X chromosome, if a pathogenic mutation is present, enzyme activity is usually significantly reduced or even near-absence. Therefore, decreased enzyme activity is a strong indication for diagnosis.
●Female: Due to the random inactivation of the X chromosome, some enzyme activity may still be retained in the body, and the test results may even fall within the normal range. Therefore, relying solely on enzyme testing is insufficient to rule out disease.
2. GLA Gene Testing
Detecting the presence of pathogenic or potentially pathogenic gene mutations can not only provide a definitive diagnosis but also be used for family screening, genetic counseling, and reproductive risk assessment. It is of great significance for the early detection of asymptomatic or mildly affected family members.
Furthermore, different mutation types may be associated with disease phenotypes and treatment responses, providing a basis for individualized management.
3. Biomarker Detection
This mainly includes plasma GL-3 and Lyso-GL-3 level measurements. Plasma GL-3 is a commonly used biochemical indicator. Male patients usually have significantly elevated levels, while female patients often have levels close to or within the normal range, thus limiting its diagnostic value for women. In contrast, plasma Lyso-GL-3 has higher sensitivity.
4. Organ Involvement Assessment
In addition to diagnostic testing, a systemic assessment of organ involvement is equally essential, including renal function tests, echocardiography or cardiac magnetic resonance imaging (MRI), and brain imaging.
III. Treatment of Fabry Disease
With the development of targeted therapy, Fabry disease has moved from being "untreatable" to a new stage where long-term intervention and management are possible. Current treatment strategies mainly revolve around enzyme replacement, molecular chaperones, and cutting-edge gene therapy.
1. Enzyme Replacement Therapy (ERT)
Enzyme replacement therapy is currently the most widely used and well-supported standard treatment. Its core principle is to reduce the deposition of globulin-3 ceramide (Gb3) in tissues by intravenously infusing recombinant α-galactosidase A (α-Gal A), thereby slowing the progression of multi-organ damage.
Commonly used drugs in international clinical practice:
●Fabrazyme (agalsidase beta)
●The pegunigalsidase Elfabrio (pegunigalsidase alfa), which has been launched in recent years, has a longer cycling half-life and different glycosylation structures, representing the direction of ERT optimization.
Multiple long-term follow-up studies have shown that continuous ERT treatment can slow the rate of renal function decline, improve or stabilize cardiac structural abnormalities such as myocardial hypertrophy, and reduce the risk of serious complications such as stroke.
2. Molecular chaperone therapy
Molecular chaperone therapy is an oral small molecule targeted regimen suitable for patients carrying specific "foldable mutations." These drugs can stabilize the structure of the mutated enzyme protein, allowing it to smoothly enter the lysosome and restore some of its activity.
For example, Galafold (migalastat) is used for patients with foldable mutations.
The main characteristics of this type of drug include:
● Oral administration, eliminating the need for intravenous infusion and improving treatment convenience.
● Applicability only to patients with certain genotypes, requiring genetic testing to assess suitability.
Therefore, this therapy emphasizes precision medicine and genotyping guidance.
3. Emerging Treatment Directions
In recent years, several cutting-edge technologies have been in clinical research, including gene therapy, mRNA therapy, and enzyme long-acting technology.
These strategies are expected to deliver long-term benefits with one or fewer treatments in the future, fundamentally changing the treatment model for Fabry disease.
IV. Why is Fabry disease easily overlooked?
The core reasons why Fabry disease has been overlooked for so long are mainly reflected in three aspects.
First, early symptoms lack specificity, such as limb pain, recurrent abdominal pain, or decreased sweating, which are also common in the general population and are easily misinterpreted as growing pains, functional gastrointestinal discomfort, or peripheral nerve problems, thus missing the opportunity for further screening.
Secondly, Fabry disease is a systemic disease affecting multiple systems, including the kidneys, heart, nervous system, and skin. However, patients often consult different departments due to varying symptoms, leading to a lack of overall correlation between these specialties and a fragmented diagnostic process.
Thirdly, doctors and the public still have limited awareness of rare diseases. In the absence of a typical family history or classic physical signs, the probability of Fabry disease being proactively considered clinically is low, further prolonging the diagnosis time.
Therefore, when unexplained renal insufficiency or renal failure, accompanied by left ventricular hypertrophy and chronic neuropathic pain, vigilance for Fabry disease should be increased, and enzyme testing and genetic screening should be performed as early as possible.
Conclusion: Rare, but not to be ignored
From early, insidious and scattered symptoms to diagnosis delays often exceeding ten years; from gradually clarifying diagnostic pathways through enzyme and genetic testing to continuously expanding treatment options through enzyme replacement, molecular chaperones, and emerging therapies—the understanding and management of Fabry disease are being rebuilt layer by layer.
For patients, earlier identification, fewer detours, and timely access to standardized follow-up and treatment remain crucial steps in determining long-term outcomes.
This is why global pharmaceutical distributor Dengyue Medicine is deeply committed to rare disease drug services, striving to shorten the distance "from diagnosis to medication," making the wait less long and enabling treatment to begin earlier.
Rare diseases may be uncommon, but every delayed life is equally real.
Being seen, understood, and treated promptly—this is where medical progress should reach, and it is the answer every patient deserves.
No comments:
Post a Comment